STOCK TITAN

If You Invested in Avita Medical, Inc. (RCEL)

Healthcare · Medical Devices · NASDAQ
Looking for the current price? See the RCEL quote & overview
$1,000 invested 1 Year Ago
$4,165
+316.5% price return
+316.5% with dividends reinvested
Bought on Nov 24, 2025 at $3.75 split-adjusted
$1,000 invested 5 Years Ago
$1,060
+6.0% price return 1.2% CAGR
+6.0% with dividends reinvested
Bought on Nov 22, 2021 at $14.74 split-adjusted

What $1,000 or $10,000 in RCEL Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Nov 23, 2015
$1,000 $4,165 +317% $1,060 +6% $1,502 +50% $2,125 +113%
$10,000 $41,653 +317% $10,597 +6% $15,019 +50% $21,252 +113%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-20. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for RCEL

$1,000 Investment Over Time

RCEL vs S&P 500

Year-by-Year Returns

RCEL annual performance
Year Start Price End Price Annual Return Cumulative
2015Nov 23 to Dec 31 $7.35 $7.40 +0.7% +0.7%
2016 $7.40 $9.20 +24.3% +25.2%
2017 $9.20 $5.35 -41.8% -27.2%
2018 $5.35 $5.60 +4.7% -23.8%
2019 $5.60 $45.50 +712.5% +519.0%
2020 $45.50 $18.58 -59.2% +152.8%
2021 $18.58 $11.98 -35.5% +63.0%
2022 $11.98 $6.60 -44.9% -10.2%
2023 $6.60 $13.72 +107.9% +86.7%
2024 $13.72 $12.80 -6.7% +74.1%
2025 $12.80 $3.45 -73.0% -53.1%
2026Dec 31, 2025 to Nov 20 $3.45 $15.62 +352.8% +112.5%

About Avita Medical, Inc.

Healthcare · NASDAQ

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) is a therapeutic acute wound care company in the surgical and medical instrument manufacturing industry. According to the company’s public disclosures, its technologies are designed to optimize wound healing and accelerate the time to patient recovery. AVITA Medical focuses on acute wound treatment, particularly thermal burn and trauma wounds, through a platform built around its RECELL System and complementary wound care products.

Core business and products

At the forefront of AVITA Medical’s platform is the RECELL System, which is approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. Company materials describe RECELL as a system that harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, used at the point-of-care. The RECELL System is intended to promote wound closure and recovery while reducing donor site burden compared with traditional split-thickness skin grafts.

In the United States, AVITA Medical also holds the rights to manufacture and the exclusive rights to market, sell, and distribute PermeaDerm, described as a biosynthetic wound matrix. In addition, the company holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical–branded collagen-based dermal matrix. Together with RECELL, these products form an integrated, multi-product acute wound care portfolio targeting burn, trauma, and related surgical settings.

Clinical evidence and role in acute wound care

AVITA Medical reports that global clinical and real-world data support the use of the RECELL System in acute wound treatment. A systematic review of peer-reviewed literature and registry analyses cited by the company describe outcomes such as reduced donor site size, faster healing, and reduced patient burden compared with traditional grafting approaches. Real-world registry data from the American Burn Association’s Burn Care Quality Platform, as referenced in company communications, highlight shorter hospital stays, higher rates of discharge to home, and favorable economic impact when RECELL is used for certain burn patients.

These findings are presented by AVITA Medical as evidence that RECELL can function as a standard of care in acute wound treatment across diverse wound types, patient populations, and care settings. The company also notes that clinical conference presentations and global analyses of thousands of patients have reinforced the clinical, operational, and economic value of the RECELL System.

Regulatory footprint and markets

AVITA Medical states that the RECELL System is approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. In international markets, the company reports that RECELL is approved to promote skin healing in a range of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe and, excluding RECELL GO, in Australia and Japan. These clearances support the company’s ability to make RECELL technology available to clinicians treating acute wounds in multiple regions.

The company has also highlighted regulatory milestones such as CE Mark approval for RECELL GO under the European Union Medical Device Regulation, enabling commercialization in European markets beginning with Germany, Italy, and the United Kingdom. In Australia, AVITA Medical has reported that the Medical Services Advisory Committee recommended amendments to the Medicare Benefits Schedule to include autologous skin cell suspension prepared with RECELL for the treatment of severe acute burn wounds in adults and children, recognizing RECELL as safe and effective with benefits in healing, donor site sparing, and reduced hospital stays.

Business focus and capital structure

AVITA Medical describes its business focus as delivering transformative acute wound care solutions and building an integrated wound care platform. Company updates emphasize efforts to strengthen its capital structure, manage operating expenses, and align spending with growth priorities. AVITA Medical has entered into credit agreements and amendments with healthcare-focused lenders, including a senior secured credit facility with Perceptive Credit Holdings V, LP and prior credit arrangements with affiliates of OrbiMed Advisors, LLC, as disclosed in its Form 8-K filings.

The company has also raised capital through equity placements, including the issuance of CHESS Depositary Interests to Australian institutional and professional investors, as reported in its SEC filings. These financing activities are described as supporting the growth of its acute wound care portfolio and providing additional financial flexibility.

Corporate governance and listing

AVITA Medical is domiciled in the United States and has its primary listing there, with its common stock trading on NASDAQ under the symbol RCEL and on the Australian Securities Exchange under the symbol AVH. The company has reported changes in its board and executive leadership through Form 8-K filings, including the appointment of an interim chief executive officer and the addition of independent directors with experience in medical technology, healthcare systems, and surgery. These governance updates are presented as steps to support the company’s long-term strategy in acute wound care.

Position within the medical device landscape

Within the broader manufacturing sector, AVITA Medical operates in surgical and medical instrument manufacturing with a specific focus on therapeutic acute wound care. Its disclosures emphasize a platform centered on autologous skin cell suspension and dermal matrices for burn and trauma care, supported by clinical evidence and regulatory approvals. Investors and clinicians reviewing AVITA Medical typically focus on the adoption and utilization of the RECELL System, the performance of PermeaDerm and Cohealyx in the company’s portfolio, regulatory developments in key markets, and the company’s ability to manage its capital structure and operating expenses.

Market Cap
$480.7M
Current Price
$15.62
EPS (FY2025)
-$1.74
Revenue (FY2025)
$71.6M
Net Margin (FY2025)
-67.8%
View full RCEL overview

Frequently Asked Questions

Avita Medical, Inc. investment returns

How much would $1,000 invested in Avita Medical, Inc. be worth today?

If you invested $1,000 in Avita Medical, Inc. (RCEL) 10 years ago on 2016-11-22, your investment would be worth $1,502 as of 2026-11-20, a +50.2% price return without dividends, growing at a compounded rate of 4.2% per year (CAGR).

Has Avita Medical, Inc. outperformed the S&P 500?

Over the past 10 years, RCEL returned +50.2% compared to +212.7% for the S&P 500, underperforming the benchmark by 162.5 percentage points.

What is Avita Medical, Inc.'s average annual return?

The compound annual growth rate (CAGR) of RCEL’s share price over the past 10 years is 4.2%, without dividends. Individual years vary a great deal, and RCEL’s best recent full year was 2019 (+712.5%) while the worst was 2025 (-73.0%).

For informational and educational purposes only, not investment advice.